Only three such biomarkers have garnered FDA approval and are widely used in clinical applications: PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability/deficiency of DNA mismatch repair (MSI/dMMR) (20). The gene discussed is CD274; the disease is neoplasm.